Physician profile
Michael S Steinberg
NPI 1902801566
$3,739.66
in general payments reported to CMS, 2019-2025
46 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $571 · 2021: $999 · 2022: $211 · 2023: $535 · 2024: $280 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509 · Education: $79.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.41 |
| Education | $79.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $499.50 | 2020-2025 | Talvey, Darzalex, Erleada |
| Pfizer INC. | $422.11 | 2019-2025 | |
| Lilly USA, LLC | $178.66 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $171.65 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $169.91 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Amgen INC. | $166.20 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Genzyme Corporation | $154.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $154.74 | 2019-2023 | |
| Incyte Corporation | $103.38 | 2020-2024 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $103.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.90 | 2020-2025 | |
| Celgene Corporation | $88.94 | 2020-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $88.90 | 2019-2025 | Trodelvy |
| Seagen INC. | $87.98 | 2020-2023 | Adcetris |
| Glaxosmithkline, LLC. | $84.68 | 2020-2023 | Zejula, Jemperli |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.